Friday, July 10, 2026
🇺🇸 FDA

pharma · Muscle-invasive bladder cancer · Unresectable intrahepatic cholangiocarcinoma

Ningbo Cancer Hospital

Ningbo Cancer Hospital clinical programs — 120 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
120
Drugs
183
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Ningbo Cancer Hospital projects

120 ClinicalTrials.gov programs sponsored by Ningbo Cancer Hospital.

Ningbo Cancer Hospital has 120 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

120 programs

Clinical programs

Page 1 of 3

  1. 1407-GUCG

    Ningbo Cancer Hospital

    Progressive or recurrent germ cell tumor (measurable or non-measurable)

    phase 3 small molecule active

    1 trial

  2. 1414-ROG-GUCG

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  3. 2022-009

    Ningbo Cancer Hospital

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  4. ALPELISIB for PIK3CA mutated HER2+ advanced o…

    Ningbo Cancer Hospital

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  5. Afinitor 5 mg tablets, PLACEBO

    Ningbo Cancer Hospital

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

  6. BAY 1841788, TRIPTORELIN

    Ningbo Cancer Hospital

    Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).

    phase 3 small molecule active

    1 trial

  7. BEATcc

    Ningbo Cancer Hospital

    Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

    phase 3 small molecule active

    1 trial

  8. CISPLATIN

    Ningbo Cancer Hospital

    Ovarian epithelial cancer : intraperitoneal resectable relapse

    phase 3 small molecule active

    1 trial

  9. CTRIAL-IE 12-01

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  10. CTRIAL-IE 14-06

    Ningbo Cancer Hospital

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  11. CTRIAL‐IE-22‐01

    Ningbo Cancer Hospital

    Early stage HER2-positive breast cancer

    phase 3 small molecule active

    1 trial

  12. Casodex® Film-coated Tablets for Localised prostate cancer at hi…

    Ningbo Cancer Hospital

    Localised prostate cancer at high risk of recurrence

    phase 3 small molecule active

    1 trial

  13. Cisplatin /ml Concentrate for Advanced head and neck cancer

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  14. EORTC-2238-GUCG

    Ningbo Cancer Hospital

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  15. EORTC-2427-BTG

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  16. FUROSEMIDE , DULOXETINE

    Ningbo Cancer Hospital

    ER positive HER2 negative breast cancer stages I-II

    phase 3 small molecule active

    1 trial

  17. GEICAM/2011-03_S1007

    Ningbo Cancer Hospital

    patients with node positive breast cancer who do not have high Recurrence Scores (RS) by Oncotype DX®

    phase 3 small molecule active

    1 trial

  18. IMFINZI for Advanced Biliary Cancer (ABC)

    Ningbo Cancer Hospital

    Advanced Biliary Cancer (ABC)

    phase 3 small molecule active

    1 trial

  19. ISRCTN12053408

    Ningbo Cancer Hospital

    Intermediate stage Hepatocellular carcinoma

    phase 3 small molecule active

    1 trial

  20. JEVTANA 60 mg concentrate and solvent for solution for infusion.

    Ningbo Cancer Hospital

    Patients with localized prostate cancer and high-risk features of relapse.

    phase 3 small molecule active

    1 trial

  21. JNJ-56021927

    Ningbo Cancer Hospital

    High-risk biochemically-relapsed prostate adenocarcinoma following radical prostatectomy.

    phase 3 small molecule active

    1 trial

  22. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    High risk resected melanoma.

    phase 3 small molecule active

    1 trial

  23. KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

    Ningbo Cancer Hospital

    Uveal Melanoma

    phase 3 small molecule active

    1 trial

  24. LOMUSTINE

    Ningbo Cancer Hospital

    Glioblastoma

    phase 3 small molecule active

    1 trial

  25. NRG-GY019

    Ningbo Cancer Hospital

    low-grade serous carcinoma of the ovary or peritoneum

    phase 3 small molecule active

    1 trial

  26. NUBEQA film-coated tablets for Localised Very High-Risk Cancer of the Prostate

    Ningbo Cancer Hospital

    Localised Very High-Risk Cancer of the Prostate

    phase 3 small molecule active

    1 trial

  27. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Patient with early triple-negative breast cancer (TNBC) achieving pathologic complete response (pCR) after neoadjuvant systemic chemotherapy and pembrolizumab.

    phase 3 small molecule active

    1 trial

  28. PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Squamous cell carcinoma of head and neck

    phase 3 small molecule active

    1 trial

  29. Placebo, CEMIPLIMAB

    Ningbo Cancer Hospital

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  30. Tecentriq 1 200 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    High-risk non-muscle invasive bladder cancer (NMIBC) after transurethral resection of the bladder (TURBT) and pathological assessment.

    phase 3 small molecule active

    1 trial

  31. UC-0103/1102

    Ningbo Cancer Hospital

    oestrogen-receptor (ER)-positive HER2-negative breast carcinoma

    phase 3 small molecule active

    1 trial

  32. UC-0103/1802

    Ningbo Cancer Hospital

    Advanced or metastatic soft tissue sarcoma (STS) in patients ≥65 years old

    phase 3 small molecule active

    1 trial

  33. UC-0107/1718

    Ningbo Cancer Hospital

    Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible for treatment with a PD-1 antagonist (pembrolizumab) according to the European Marketing Authorisation in a first line

    phase 3 small molecule active

    1 trial

  34. UC-0110/1609

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  35. UC-0140/1615

    Ningbo Cancer Hospital

    ER+/HER2- metastatic breast cancer

    phase 3 small molecule active

    1 trial

  36. UC-0140/1901

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  37. UC-0160/1003

    Ningbo Cancer Hospital

    Prostatic adenocarnicoma with high risk of recurrence

    phase 3 small molecule active

    1 trial

  38. UC-BCG-2409/BIG 2402

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  39. UC-BCG-2501

    Ningbo Cancer Hospital

    Patients with HR+ HER2- early breast cancer at intermediate risk of recurrence and eligible for adjuvant chemotherapy

    phase 3 small molecule active

    1 trial

  40. UC-GIG-2406

    Ningbo Cancer Hospital

    Patients with hepatocellular carcinoma with high tumor burden.

    phase 3 small molecule active

    1 trial

  41. UC-GIG-2408

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  42. UC-GIG-2410

    Ningbo Cancer Hospital

    Stage III colorectal cancer

    phase 3 small molecule active

    1 trial

  43. UC-GTG-2301

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  44. UC-GTG-2306

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  45. UC-IMM-2101

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  46. Xofigo 1100 kBq/mL solution for injection

    Ningbo Cancer Hospital

    metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  47. Xtandi - soft capsules for Castration resistant prostate c…

    Ningbo Cancer Hospital

    Castration resistant prostate cancer patients metastatic to bone.

    phase 3 small molecule active

    1 trial

  48. Zometa 4 mg/100 ml solution for infusion

    Ningbo Cancer Hospital

    High grade osteosarcoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Ningbo Cancer Hospital have?

120 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.